HER3 mRNA as a predictive biomarker in anticancer therapy.
about
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyHER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsHematogenous metastasis of ovarian cancer: rethinking mode of spread.Prognostic biomarkers in ovarian cancer.High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells
P2860
HER3 mRNA as a predictive biomarker in anticancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HER3 mRNA as a predictive biomarker in anticancer therapy.
@en
HER3 mRNA as a predictive biomarker in anticancer therapy.
@nl
type
label
HER3 mRNA as a predictive biomarker in anticancer therapy.
@en
HER3 mRNA as a predictive biomarker in anticancer therapy.
@nl
prefLabel
HER3 mRNA as a predictive biomarker in anticancer therapy.
@en
HER3 mRNA as a predictive biomarker in anticancer therapy.
@nl
P2860
P1476
HER3 mRNA as a predictive biomarker in anticancer therapy.
@en
P2093
Lukas C Amler
P2860
P304
P356
10.1517/14712598.2010.512003
P407
P577
2010-09-01T00:00:00Z